Search

CN-122005492-A - Nanometer material for treating endometriosis and application thereof

CN122005492ACN 122005492 ACN122005492 ACN 122005492ACN-122005492-A

Abstract

The invention discloses a nano material for treating endometriosis and application thereof, belonging to the technical field of biological medicine and nano medicine delivery. The nano material is ACS14@BSA nano particles, and the ACS14@BSA nano particles take BSA as a carrier and are loaded with hydrogen sulfide release type aspirin ACS14.BSA is a carrier, focus selective enrichment can be realized through a neutrophil carrying mechanism, ACS14 can play roles in inhibiting proliferation and resisting inflammation at a focus, the recurrence risk is reduced, hydrogen sulfide released at the focus can act on a front cingulate skin layer through blood circulation, GLT-1 is up-regulated, extracellular glutamic acid is reduced, neuronal hyperexcitation is inhibited, and related anxiety is relieved. The invention can realize focus targeting delivery, inhibit proliferation and anti-inflammatory treatment, synchronously improve related anxiety, and realize comprehensive treatment of endometriosis and related anxiety and other complications.

Inventors

  • ZHU SHASHA
  • ZHOU MENGNI
  • ZHANG JIQIAN

Assignees

  • 安徽医科大学第一附属医院

Dates

Publication Date
20260512
Application Date
20260204

Claims (10)

  1. 1. A nanomaterial for treating endometriosis is characterized by being ACS14@BSA nanoparticles, wherein the ACS14@BSA nanoparticles take BSA as a carrier and are loaded with hydrogen sulfide release type aspirin ACS14.
  2. 2. The nanomaterial for treating endometriosis according to claim 1, wherein raw materials of the ACS14@BSA nanoparticles comprise (2.5-3.5) BSA and hydrogen sulfide releasing aspirin ACS14 in a mass ratio of 10.
  3. 3. The nanomaterial for treating endometriosis according to claim 1, wherein the drug loading rate of the hydrogen sulfide release type aspirin ACS14 is 8.9-11.5%.
  4. 4. The nanomaterial for treating endometriosis according to claim 1, characterized in that the particle size of the acs14@bsa nanoparticles is 200-250 nm.
  5. 5. Nanomaterial for the treatment of endometriosis according to claim 1, characterized in that the acs14@bsa nanoparticles are prepared according to the following method: s1, adding BSA into deionized water and stirring and dissolving at room temperature to obtain a BSA aqueous solution, adding ACS14 into dimethyl sulfoxide and stirring and dissolving to obtain an ACS14 solution; s2, adding ACS14 solution into BSA aqueous solution, and stirring and mixing at room temperature to obtain mixed solution; s3, dropwise adding absolute ethyl alcohol into the mixed solution, uniformly stirring, then adding a cross-linking agent solution with the mass fraction of 2-3%, and stirring and reacting for 5-6 hours to obtain a reaction solution; S4, centrifuging the reaction solution at 4-5 ℃ for 10-15 min, collecting precipitate, re-suspending with ultrapure water, uniformly mixing by vortex, performing centrifugal washing for 2-3 times, and finally adding the mixture into buffer solution for re-dispersing.
  6. 6. The nanomaterial for treating endometriosis of claim 5, wherein the cross-linking agent comprises glutaraldehyde.
  7. 7. The nanomaterial for treating endometriosis as claimed in claim 5, wherein the mass volume ratio of the BSA, the absolute ethanol and the cross-linking agent solution is 10mg (3-3.5) mL (8-15) μl.
  8. 8. Use of a nanomaterial for the treatment of endometriosis, based on a nanomaterial for the treatment of endometriosis according to any of claims 1 to 7, characterized in that the nanomaterial is used for the treatment of endometriosis or for the preparation of a medicament for the treatment of endometriosis.
  9. 9. The use of nanomaterial for the treatment of endometriosis as claimed in claim 8, wherein the nanomaterial is used for the treatment of psychological co-diseases such as anxiety caused by endometriosis or for the preparation of a medicament for the treatment of psychological co-diseases such as anxiety caused by endometriosis.
  10. 10. The use of nanomaterial for the treatment of endometriosis as claimed in claim 8, wherein the nanomaterial is used for simultaneous treatment of endometriosis and anxiety associated with endometriosis or for the preparation of a medicament for simultaneous treatment of endometriosis and anxiety associated with endometriosis.

Description

Nanometer material for treating endometriosis and application thereof Technical Field The invention relates to the technical field of biological medicine and nano-drug delivery, in particular to a nano-material for treating endometriosis and application thereof. Background Endometriosis (Endometriosis, EMs) is a common chronic inflammatory gynaecological disease, mainly manifested by endometrioid tissue ectopic growth, which can cause dysmenorrhea, pelvic pain and infertility, severely reducing the quality of life of the patient. The occurrence and development of endometriosis is closely related to abnormal proliferation of ectopic cells, sustained activation of inflammatory response and disturbance of immune microenvironment. At present, the treatment means of endometriosis mainly comprises surgery and hormone treatment, but the surgery excision can reduce focus load in a short period of time, but has high recurrence rate and possibly even influence on fertility function, and the hormone treatment can inhibit focus progress, but is extremely easy to recur after stopping medicine, and side effects such as weight increase, mood fluctuation and the like can be caused, while the traditional anti-inflammatory and analgesic drugs are mostly symptomatic relief, and focus is difficult to control from the aspects of proliferation and inflammatory mechanisms. Therefore, there is an urgent need for a new therapeutic approach for endometriosis that is non-surgical, non-hormonal, and can fundamentally control lesions and reduce side effects. In addition, endometriosis is often accompanied with psychological co-diseases such as anxiety, and the occurrence rate of anxiety, depression and the like of patients is obviously higher than that of healthy people, but the existing anxiolytic drugs mainly aim at mental symptoms, are difficult to realize symptomatic treatment, are difficult to consider focus control, can bring adverse reactions, can have risks such as somnolence, dependence and the like, and cannot realize comprehensive management of physical and mental co-treatment. The hydrogen sulfide has certain anti-inflammatory and nerve regulation potential, but the release and metabolism of the hydrogen sulfide in a physiological environment are rapid, and the problems of uncontrollable release, poor targeted distribution and the like exist in clinical application, so that the clinical application of the hydrogen sulfide is severely limited. While nanotechnology provides a new solution for drug delivery, most of existing nanodrug delivery systems emphasize local targeting or single drug effect, and are difficult to realize uniform improvement of different symptoms at the same time. Therefore, in order to solve the problems of the endometriosis patients in both focus treatment and anxiety improvement, it is important to develop a novel endometriosis treatment method with low recurrence rate and small side effects. Disclosure of Invention The invention provides a nano material for treating endometriosis and application thereof, which can solve the problems of high recurrence rate, large side effect and difficulty in solving focus treatment and anxiety improvement in the treatment of endometriosis in the prior art. In a first aspect, the invention provides a nanomaterial for treating endometriosis, which is ACS14@BSA nanoparticles, wherein the ACS14@BSA nanoparticles take BSA as a carrier and are loaded with hydrogen sulfide release type aspirin ACS14. Preferably, the raw materials of the ACS14@BSA nano particles comprise (2.5-3.5) BSA and hydrogen sulfide release type aspirin ACS14 in a mass ratio of 10. Preferably, the drug loading rate of the hydrogen sulfide release type aspirin ACS14 is 8.9-11.5%. Preferably, the particle size of the ACS14@BSA nanoparticles is 200-250 nm. Preferably, the ACS14@BSA nanoparticle is prepared by the following method: s1, adding BSA into deionized water and stirring and dissolving at room temperature to obtain a BSA aqueous solution, adding ACS14 into dimethyl sulfoxide and stirring and dissolving to obtain an ACS14 solution; s2, adding ACS14 solution into BSA aqueous solution, and stirring and mixing at room temperature to obtain mixed solution; s3, dropwise adding absolute ethyl alcohol into the mixed solution, uniformly stirring, then adding a cross-linking agent solution with the mass fraction of 2-3%, and stirring and reacting for 5-6 hours to obtain a reaction solution; S4, centrifuging the reaction solution at 4-5 ℃ for 10-15 min, collecting precipitate, re-suspending with ultrapure water, uniformly mixing by vortex, performing centrifugal washing for 2-3 times, and finally adding the mixture into buffer solution for re-dispersing. Preferably, the cross-linking agent comprises glutaraldehyde. Preferably, the mass volume ratio of the BSA, the absolute ethyl alcohol and the cross-linking agent solution is 10mg (3-3.5) mL (8-15) mu L. More preferably, the buffer comprises a PBS buffer. By